πŸ‡ΊπŸ‡Έ FDA
Patent

US 12414983

CD200AR ligands for cancer immunotherapy

granted A61KA61K2039/5152A61K2039/545

Quick answer

US patent 12414983 (CD200AR ligands for cancer immunotherapy) held by Regents of the University of Minnesota expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/5152, A61K2039/545, A61K2039/552, A61K2039/572